Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Other Accumulated Expenses (2016 - 2023)

Historic Other Accumulated Expenses for Editas Medicine (EDIT) over the last 9 years, with Q2 2023 value amounting to $78000.0.

  • Editas Medicine's Other Accumulated Expenses fell 9717.6% to $78000.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $78000.0, marking a year-over-year decrease of 9717.6%. This contributed to the annual value of $1.6 million for FY2022, which is 1612.22% up from last year.
  • Latest data reveals that Editas Medicine reported Other Accumulated Expenses of $78000.0 as of Q2 2023, which was down 9717.6% from $109000.0 recorded in Q1 2023.
  • In the past 5 years, Editas Medicine's Other Accumulated Expenses ranged from a high of $4.0 million in Q2 2020 and a low of $78000.0 during Q2 2023
  • Its 5-year average for Other Accumulated Expenses is $1.5 million, with a median of $1.3 million in 2020.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 28983.54% in 2020, then crashed by 9717.6% in 2023.
  • Editas Medicine's Other Accumulated Expenses (Quarter) stood at $2.7 million in 2019, then crashed by 57.87% to $1.1 million in 2020, then grew by 24.6% to $1.4 million in 2021, then grew by 16.12% to $1.6 million in 2022, then crashed by 95.23% to $78000.0 in 2023.
  • Its Other Accumulated Expenses was $78000.0 in Q2 2023, compared to $109000.0 in Q1 2023 and $1.6 million in Q4 2022.